ICICI Securities Limited
Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests. In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25.
Metropolis Healthcare Ltd.'s price crossed above 30Day SMA today
More from Metropolis Healthcare Ltd.
Recommended